These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 7585182)

  • 21. Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo.
    Gibbs JB; Pompliano DL; Mosser SD; Rands E; Lingham RB; Singh SB; Scolnick EM; Kohl NE; Oliff A
    J Biol Chem; 1993 Apr; 268(11):7617-20. PubMed ID: 8463291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
    Lantry LE; Zhang Z; Yao R; Crist KA; Wang Y; Ohkanda J; Hamilton AD; Sebti SM; Lubet RA; You M
    Carcinogenesis; 2000 Jan; 21(1):113-6. PubMed ID: 10607742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oreganic acid, a potent inhibitor of ras farnesyl-protein transferase.
    Silverman KC; Jayasuriya H; Cascales C; Vilella D; Bills GF; Jenkins RG; Singh SB; Lingham RB
    Biochem Biophys Res Commun; 1997 Mar; 232(2):478-81. PubMed ID: 9125205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase.
    Anthony NJ; Gomez RP; Schaber MD; Mosser SD; Hamilton KA; O'Neil TJ; Koblan KS; Graham SL; Hartman GD; Shah D; Rands E; Kohl NE; Gibbs JB; Oliff AI
    J Med Chem; 1999 Aug; 42(17):3356-68. PubMed ID: 10464022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of farnesyl protein transferase by monoterpene, curcumin derivatives and gallotannin.
    Chen X; Hasuma T; Yano Y; Yoshimata T; Morishima Y; Wang Y; Otani S
    Anticancer Res; 1997; 17(4A):2555-64. PubMed ID: 9252680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selection of potent inhibitors of farnesyl-protein transferase from a synthetic tetrapeptide combinatorial library.
    Wallace A; Koblan KS; Hamilton K; Marquis-Omer DJ; Miller PJ; Mosser SD; Omer CA; Schaber MD; Cortese R; Oliff A; Gibbs JB; Pessi A
    J Biol Chem; 1996 Dec; 271(49):31306-11. PubMed ID: 8940136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A combined treatment of HeLa cells with the farnesyl protein transferase inhibitor L-744,832 and cisplatin significantly increases the therapeutic effect as compared to cisplatin monotherapy.
    Wesierska-Gadek J; Kramer MP; Schmid G
    J Cell Biochem; 2008 May; 104(1):189-201. PubMed ID: 18022825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
    Feldkamp MM; Lau N; Guha A
    Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl:protein transferase inhibitor.
    Ito T; Kawata S; Tamura S; Igura T; Nagase T; Miyagawa JI; Yamazaki E; Ishiguro H; Matasuzawa Y
    Jpn J Cancer Res; 1996 Feb; 87(2):113-6. PubMed ID: 8609057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors.
    Bearss DJ; Subler MA; Hundley JE; Troyer DA; Salinas RA; Windle JJ
    Oncogene; 2000 Feb; 19(8):1114-22. PubMed ID: 10713698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228.
    Prevost GP; Pradines A; Brezak MC; Lonchampt MO; Viossat I; Ader I; Toulas C; Kasprzyk P; Gordon T; Favre G; Morgan B
    Int J Cancer; 2001 Mar; 91(5):718-22. PubMed ID: 11267986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitors of farnesyl:protein transferase--a possible cancer chemotherapeutic.
    Scholten JD; Zimmerman K; Oxender M; Sebolt-Leopold J; Gowan R; Leonard D; Hupe DJ
    Bioorg Med Chem; 1996 Sep; 4(9):1537-43. PubMed ID: 8894110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.
    Leftheris K; Kline T; Vite GD; Cho YH; Bhide RS; Patel DV; Patel MM; Schmidt RJ; Weller HN; Andahazy ML; Carboni JM; Gullo-Brown JL; Lee FY; Ricca C; Rose WC; Yan N; Barbacid M; Hunt JT; Meyers CA; Seizinger BR; Zahler R; Manne V
    J Med Chem; 1996 Jan; 39(1):224-36. PubMed ID: 8568812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer.
    Moasser MM; Rosen N
    Breast Cancer Res Treat; 2002 May; 73(2):135-44. PubMed ID: 12088116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kampanols: novel Ras farnesyl-protein transferase inhibitors from Stachybotrys kampalensis.
    Singh SB; Zink DL; Williams M; Polishook JD; Sanchez M; Silverman KC; Lingham RB
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2071-6. PubMed ID: 9873488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice.
    Kohl NE; Wilson FR; Mosser SD; Giuliani E; deSolms SJ; Conner MW; Anthony NJ; Holtz WJ; Gomez RP; Lee TJ
    Proc Natl Acad Sci U S A; 1994 Sep; 91(19):9141-5. PubMed ID: 8090782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Photoaffinity-labeling peptide substrates for farnesyl-protein transferase and the intersubunit location of the active site.
    Ying W; Sepp-Lorenzino L; Cai K; Aloise P; Coleman PS
    J Biol Chem; 1994 Jan; 269(1):470-7. PubMed ID: 8276838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of parathyroid hormone-related peptide by the Ras oncogene: role of Ras farnesylation inhibitors as potential therapeutic agents for hypercalcemia of malignancy.
    Aklilu F; Park M; Goltzman D; Rabbani SA
    Cancer Res; 1997 Oct; 57(20):4517-22. PubMed ID: 9377563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.
    Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Lipari P; Malkowski M; Ferrari E; Nielsen L; Prioli N; Dell J; Sinha D; Syed J; Korfmacher WA; Nomeir AA; Lin CC; Wang L; Taveras AG; Doll RJ; Njoroge FG; Mallams AK; Remiszewski S; Catino JJ; Girijavallabhan VM; Bishop WR
    Cancer Res; 1998 Nov; 58(21):4947-56. PubMed ID: 9810004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Farnesyl protein transferase inhibitors as potential cancer chemopreventives.
    Kelloff GJ; Lubet RA; Fay JR; Steele VE; Boone CW; Crowell JA; Sigman CC
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):267-82. PubMed ID: 9107432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.